veligrotug   Click here for help

GtoPdb Ligand ID: 14572

Synonyms: AVE-1642 | AVE1642 | Lumvoa®: | veligrotug-vvze | VRDN-001
Approved drug Immunopharmacology Ligand
veligrotug is an approved drug
Compound class: Antibody
Comment: Veligrotug (AVE-1642) is a monoclonal antibody that targets insulin-like growth factor 1 receptor (IGF1R) [4].
Click here for help
References
1. Girnita L, Smith TJ, Janssen JAMJL. (2022)
It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease.
J Clin Endocrinol Metab, 107 (Suppl_1): S1-S12. [PMID:35167695]
2. Iams WT, Lovly CM. (2015)
Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.
Clin Cancer Res, 21 (19): 4270-7. [PMID:26429980]
3. Kamboj A, Harrison AR, Mokhtarzadeh A. (2023)
Emerging therapies in the medical management of thyroid eye disease.
Front Ophthalmol (Lausanne), 3: 1295902. [PMID:38983101]
4. Kaplan R, Zhao Y, Tsai J, Dickinson B, Swanson T, Foster K, Bedian V. (2025)
Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease.
MAbs, 17 (1): 2585616. [PMID:41250603]
5. Krieger CC, Sui X, Kahaly GJ, Neumann S, Gershengorn MC. (2022)
Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease.
J Clin Endocrinol Metab, 107 (4): e1653-e1660. [PMID:34788857]
6. Latif R, Mezei M, Davies TF. (2025)
Mechanisms in Thyroid Eye Disease: The TSH Receptor Interacts Directly With the IGF-1 Receptor.
Endocrinology, 166 (2). [PMID:39821041]
7. McGuigan A. (2026)
Veligrotug: First Approval.
Drugs, [Epub ahead of print]. [PMID:42864578]
8. Scagliotti GV, Novello S. (2012)
The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors.
Cancer Treat Rev, 38 (4): 292-302. [PMID:21907495]
9. Smith TJ. (2025)
Thyroid eye disease and the IGF-1 receptor.
Lancet Diabetes Endocrinol, 13 (9): 741-742. [PMID:40812955]
10. Sohail A, Mushtaq A, Iftikhar A, Warraich Z, Kurtin SE, Tenneti P, McBride A, Anwer F. (2018)
Emerging immune targets for the treatment of multiple myeloma.
Immunotherapy, 10 (4): 265-282. [PMID:29421983]
11. Yen MT, Cockerham K, Saeed P, Leibowitz S, Mudumbai RC, Schittkowski MP, Lee V, Abrams J, Turbin RE, Pío-Rendón JB et al.. (2026)
THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease.
Ophthalmology, [Epub ahead of print]. [PMID:42223386]